Yifan Pharma’s unit, eyeing US$5.5 billion post-chemotherapy treatment market dominated by Amgen, considers IPO in 2021
Evive’s F-627 candidate has shown promising results after several phase three clinical trials, CEO Liu Jubo saysAmgen’s second best-seller Neulasta, whose patent exp...


















